Dexpramipexole Dosing for Eosinophilic Asthma Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for moderate to severe asthma of the eosinophilic phenotype are inadequate in reducing eosinophil levels in both peripheral blood and lung tissues, leading to uncontrolled symptoms and frequent exacerbations, despite the use of standard asthma medications like inhaled corticosteroids and long-acting beta agonists.
Innovation Solution
Oral administration of dexpramipexole, a synthetic aminobenzothiazole derivative, in doses ranging from 75 mg to 300 mg daily, effectively reduces eosinophil levels in both peripheral blood and lung tissues, improving lung function and reducing asthma exacerbations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard asthma medications (inhaled corticosteroids and long-acting beta agonists) are used, then asthma symptoms are partially controlled, but eosinophil levels in peripheral blood and lung tissues remain elevated
Solution Approach 1:
The patent introduces a new pharmacological parameter (dexpramipexole) that specifically targets eosinophil reduction. This compound modifies the eosinophil count parameter independently from standard asthma medications, achieving a dual effect: maintaining symptom control while specifically reducing eosinophil levels in both peripheral blood and lung tissues.
Solution Approach 2:
Dexpramipexole acts as an intermediary substance that bridges the gap between standard asthma treatment and eosinophil reduction. It can be combined with inhaled corticosteroids and long-acting beta agonists to provide additive benefit, specifically targeting the eosinophilic component of asthma pathology that standard medications do not adequately address.
2Quantity of substance
If standard asthma medications are increased to reduce eosinophil levels, then eosinophil reduction is achieved, but treatment complexity and potential side effects increase
Solution Approach 1:
The treatment approach is segmented into two distinct components: standard asthma medications (inhaled corticosteroids and long-acting beta agonists) for general asthma control, and dexpramipexole for specific eosinophil reduction. This segmentation allows each component to target its specific function without requiring excessive dosing of a single agent, thereby reducing overall treatment complexity.
Solution Approach 2:
Dexpramipexole serves multiple functions simultaneously: it reduces peripheral blood eosinophils, decreases lung tissue eosinophils, and provides additive asthma symptom control. This multi-functionality eliminates the need for multiple separate interventions, simplifying the overall treatment regimen while achieving comprehensive eosinophil reduction.
3Quantity of substance
If higher doses of dexpramipexole are administered, then eosinophil reduction is enhanced, but safety and tolerability concerns arise
Solution Approach 1:
The patent applies partial action by using dexpramipexole at doses that provide sufficient eosinophil reduction without achieving complete elimination. This partial reduction is clinically adequate for improving asthma control and reducing exacerbations, while avoiding the excessive dosing that would cause safety and tolerability issues. The dose-response relationship is optimized to achieve the minimum effective reduction.
Data Source
AI summary
Disclosed herein are methods of treating moderate to severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 75 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof, and treating severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 150 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof.